Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reckitt Benckiser Plc ADR (OP: RBGLY )

10.98 +0.12 (+1.10%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 401,941
Open 10.97
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 10.86
Today's Range 10.91 - 11.00
52wk Range 10.24 - 15.56
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With Abbott Laboratories Stock On Friday?
An Illinois jury orders Reckitt Benckiser's Mead Johnson to pay $60 million after a premature infant's tragic death linked to Enfamil baby formula. Mead Johnson found negligent for not warning about... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Durex Owner Reckitt Benckiser Taps Into China's Livestreaming Trend To Sell Condoms Online
Reckitt Benckiser Group is leveraging the popularity of livestream shopping in China to sell condoms, a move that could be challenging due to strict regulatory oversight. 
Via Benzinga

Performance

YTD
-20.15%
-20.15%
1 Month
-5.75%
-5.75%
3 Month
+1.76%
+1.76%
6 Month
-21.63%
-21.63%
1 Year
-26.51%
-26.51%

More News

Read More
NVDA Stock on Fire: Can Potential Nvidia Investors Still Get In or Will They Get Burned?
Via InvestorPlace
Reckitt's Mead Johnson Initiates Massive Recall Of 675K Cans Of Hypoallergenic Baby Formula Over Bacteria Contamination Fears
Via Benzinga
Pumpkin Spice Profits: Take a Sip of SBUX Stock Before the End of the Year
Via InvestorPlace
Carlyle Pays $300M For Majority Ownership In India's VLCC
Via Benzinga
British Consumer Company Reckitt Benckiser's CEO Steps Down
Via Benzinga
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
Via Benzinga
Exposures Product Safety
3 Consumer Staples Stocks to Dump ASAP
Via InvestorPlace
Is There Collusion in the Baby-Formula Industry?: FTC Scrutinizes State Contracts Bidding Process
Via Benzinga
7 Established Stocks That Are Poised for Growth in 2023
Via InvestorPlace
Abbott Laboratories Under DOJ Investigation Into 2022 Baby Formula Plant Shutdown: Report
Via Benzinga
The Viral “Tripledemic” Opportunity
Via Talk Markets
Reckitt Sees US Baby Food Formula Crisis Persisting Till Spring: Report
Via Benzinga
The “Procter & Gamble Of The UK” Is Now On My Watchlist
Via Talk Markets
Short Volatility Alert: Reckitt Benckiser Group plc
Via Benzinga
New Starbucks CEO To Focus On Unions, Pay And Benefits As Part Of 'Reinvention' Plan
Via Benzinga
Why This Starbucks Analyst Is Surprised By New CEO Choice — And Optimistic
Via Benzinga
Baby Formula Startup Seeks To Compete Abbott With 15% Market Share: Report
Via Benzinga
Benzinga Before The Bell: Twitter Shareholder Proposal Date Set, T-Mobile's Strong FY22 Outlook, Shopify's Job Cuts And Other Top Financial Stories Wednesday, July 27
Via Benzinga
Reckitt Lifts Annual Forecast On Higher Prices, Baby Formula Shortage
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Wednesday, May 25
Via Benzinga
More Companies Join Race To Ease US Baby Formula Supply Crunch
Via Benzinga
Danone Scales Up Baby Formula Shipments To US To Combat Shortage: Reuters
Via Benzinga
ABT Stock Climbs as Abbott Reaches a Baby Formula Deal With the FDA
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.